NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04099251 2026-04-09CheckMate76KBristol-Myers SquibbPhase 3 Active not recruiting790 enrolled 18 charts 2 FDA
NCT03969004 2026-03-27Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaRegeneron PharmaceuticalsPhase 3 Active not recruiting415 enrolled 2 FDA